Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $245.6 million.

  • Revolution Medicines' Total Current Liabilities rose 121.55% to $245.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.6 million, marking a year-over-year increase of 121.55%. This contributed to the annual value of $163.9 million for FY2024, which is 13.95% up from last year.
  • Per Revolution Medicines' latest filing, its Total Current Liabilities stood at $245.6 million for Q3 2025, which was up 33.10% from $184.5 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Total Current Liabilities ranged from a high of $245.6 million in Q3 2025 and a low of $43.8 million during Q1 2021.
  • Its 3-year average for Total Current Liabilities is $129.5 million, with a median of $110.9 million in 2024.
  • Examining YoY changes over the last 5 years, Revolution Medicines' Total Current Liabilities showed a top increase of 132.08% in 2023 and a maximum decrease of 4.91% in 2023.
  • Revolution Medicines' Total Current Liabilities (Quarterly) stood at $60.4 million in 2021, then increased by 2.71% to $62.0 million in 2022, then spiked by 132.08% to $143.9 million in 2023, then climbed by 13.95% to $163.9 million in 2024, then surged by 121.55% to $245.6 million in 2025.
  • Its last three reported values are $245.6 million in Q3 2025, $184.5 million for Q2 2025, and $158.6 million during Q1 2025.